← Back to Search

Virus Therapy

Live Attenuated Tularemia Vaccine for Tularemia (NDBR Trial)

Phase 2
Waitlist Available
Led By Benjamin C Pierson, MD
Research Sponsored by U.S. Army Medical Research and Development Command
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

NDBR Trial Summary

This trial will test the safety and effectiveness of a new tularemia vaccine.

NDBR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Microagglutination (MA) titer that shows a greater than or equal to 4 fold rise in antibody titer after vaccination
Number of erythematous papule, vesicle and/or eschar with or without underlying induration
Secondary outcome measures
Number of tularemia cases following exposure to F. tularensis in a successfully vaccinated individual

NDBR Trial Design

1Treatment groups
Experimental Treatment
Group I: Live Attenuated Tularemia VaccineExperimental Treatment1 Intervention
0.06 mL of Tularemia Vaccine, Live, Attenuated, NDBR 101, Lot 4

Find a Location

Who is running the clinical trial?

US Army Medical Research Institute of Infectious DiseasesFED
13 Previous Clinical Trials
1,388 Total Patients Enrolled
U.S. Army Medical Research and Development CommandLead Sponsor
285 Previous Clinical Trials
245,159 Total Patients Enrolled
2 Trials studying Tularemia
1,484 Patients Enrolled for Tularemia
Benjamin C Pierson, MDPrincipal InvestigatorUSAMRIID

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research encompass participants aged 40 or above?

"The upper age limit for participants in this trial is 65 years old, while the minimum age of consent applies."

Answered by AI

Is enrollment for this research project still open?

"Data on clinicaltrials.gov displays that this medical trial is not actively enrolling participants right now, as the last update was made in February 2021. However, there are presently other trials accepting applicants."

Answered by AI

What potential hazards should be considered when administering Live Attenuated Tularemia Vaccine?

"Our team has judged the safety of Live Attenuated Tularemia Vaccine to be a 2. This is due to its status as a Phase 2 trial which demonstrates some data supporting safety, but no evidence for efficacy."

Answered by AI

Who meets the criteria to partake in this research endeavor?

"This medical trial is recruiting 500 subjects suffering from tularemia, all of whom should be within the age range 18-65. Criteria for applicant acceptance include risk exposure to Francisella tularensis (Ftularensis) and a signed Request for IND Vaccines regarding their vaccine status, agreement to report any adverse events 28 days after administration or serious consequences during study duration, submission to follow-up visits, clearance by an investigator with possible exams/tests repeat at PI's discretion, deferment of blood donation in 1 year post vaccination."

Answered by AI
~0 spots leftby Mar 2025